ESMO Breast 2023 | ILC: a commonly overlooked subtype of breast cancer

Karen Van Baelen, MD, KU Leuven, Leuven, Belgium, comments on the lack of invasive lobular breast cancer (ILC) representation within clinical trials, and the potential implications that may ensue as a result of this oversight. Dr Van Baelen explains that as many clinical trials often fail to include the number of patients with ILC included within the study, where this subpopulation of patients can commonly feel ignored and underrepresented in the literature. This interview took place at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.